Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-05-30, Stock:LLY, The news for the past five days is as follows:
2018-05-22: NEWS1: Why Did JNJ Scrap Its Alzheimer’s Drug Mid-Stage Trial?.NEWS2: Amgen's Label Expansion Application for Prolia Gets FDA Nod.NEWS3: Amgen's Label Expansion Application for Prolia Gets FDA Nod.NEWS4: Eli Lilly’s Elanco in Q1 2018.NEWS5: Eli Lilly’s Cardiovascular Products in Q1 2018.NEWS6: Lilly's Taltz® (ixekizumab) Receives the First U.S. FDA Approval for Label Update to Include Data for Psoriasis Involving the Genital Area.NEWS7: Eli Lilly’s Oncology Products in Q1 2018.NEWS8: Eli Lilly And Co. To Present At UBS Global Conference; Webcast At 10:30 AM ET.NEWS9: Eli Lilly And Co. To Present At UBS Global Conference; Webcast At 10:30 AM ET.NEWS10: Eli Lilly: FDA Approves Label Update For Taltz - Quick Facts.NEWS11: Eli Lilly: FDA Approves Label Update For Taltz - Quick Facts.
2018-05-23: NEWS1: Sue Mahony to Retire as President of Lilly Oncology.NEWS2: Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs.NEWS3: Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis.NEWS4: Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis.NEWS5: Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis.NEWS6: Teva hopes to launch migraine drug as soon as September.NEWS7: Elanco, Heifer International 10-Year Effort Breaks the Cycle of Hunger for 160,000 Families.NEWS8: Analyst Recommendations for Eli Lilly on May 17.
2018-05-24: NEWS1: FDA Confirms September Action Date for Teva's Migraine Drug.NEWS2: FDA Confirms September Action Date for Teva's Migraine Drug.NEWS3: FDA Confirms September Action Date for Teva&apos;s Migraine Drug.NEWS4: Why Is Eli Lilly (LLY) Up 2.7% Since Its Last Earnings Report?.NEWS5: Why Is Eli Lilly (LLY) Up 2.7% Since Its Last Earnings Report?.NEWS6: Merck's Keytruda Shows Survival Benefit in Squamous NSCLC.NEWS7: Merck's Keytruda Shows Survival Benefit in Squamous NSCLC.NEWS8: Noteworthy ETF Outflows: IWF, COST, CRM, LLY.NEWS9: Noteworthy ETF Outflows: IWF, COST, CRM, LLY.NEWS10: Why Is Eli Lilly (LLY) Up 2.7% Since Its Last Earnings Report?.NEWS11: Is This Little Biotech the Best Migraine Stock to Buy Now?.NEWS12: Is This Little Biotech the Best Migraine Stock to Buy Now?.NEWS13: Is This Little Biotech the Best Migraine Stock to Buy Now?.NEWS14: An Upgrade for This Wellington-Managed Fund of Dividend Payers.
2018-05-25: NEWS1: Teva’s Fremanezumab Gets September Action Date from FDA.NEWS2: Barclays Raises Its 12-Month Target Price on Teva Stock.NEWS3: A Brief Overview of Merck’s First-Quarter Performance.NEWS4: Dow 30 Stock Roundup: GE's Transportation Unit to Merge With Wabtec, J&J & Glaxo's HIV Drug Gets EU Approval.NEWS5: Dow 30 Stock Roundup: GE's Transportation Unit to Merge With Wabtec, J&J & Glaxo's HIV Drug Gets EU Approval.
2018-05-29: NEWS1: Novo Nordisk's oral diabetes drug beats Jardiance in study.NEWS2: Analyzing Incyte’s Revenue Stream in Q1 2018.NEWS3: An Overview Merck’s Diabetes and Women’s Health Portfolios.NEWS4: Incyte’s Revenue Trend in Q1 2018.

Answer: Rise